Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate The Safety and Efficacy of STRI Formula in Non-Hospitalized Participants With COVID-19

NCT05046561 is registered in ClinicalTrials.gov with Eyecheck, Inc. as lead sponsor.

NCT NCT05046561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05046561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate The Safety and Efficacy of STRI Formula in Non-Hospitalized Participants With COVID-19
Lead sponsor
Eyecheck, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
November 4, 2021
Completion date
August 31, 2023
Enrollment
598 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

covid19